C Anne Higley

Title: C Anne Higley: Innovator in Antineoplastic and Atherosclerosis Treatments

Introduction

C Anne Higley is a prominent inventor based in Newark, DE (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of targeted therapies for cancer and atherosclerosis. With a total of 6 patents to her name, Higley's work has the potential to impact the treatment landscape for these serious health conditions.

Latest Patents

Higley's latest patents include groundbreaking inventions such as "Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use." This invention focuses on antineoplastic agents that are conjugated to enzyme-cleavable peptides, which contain the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase. These compounds are designed for targeted chemotherapy in cancer treatment. Another notable patent is "Fused-ring heterocycles for the treatment of atherosclerosis," which involves pyrazolo pyrimidines that act as inhibitors of acyl-CoA cholesterol acyltransferase (ACAT). This invention aims to provide antihypercholesterolemic agents and pharmaceutical compositions for the treatment of atherosclerosis.

Career Highlights

Throughout her career, C Anne Higley has worked with esteemed organizations such as the DuPont Merck Pharmaceutical Company and Bristol-Myers Squibb Pharma Company. Her experience in these companies has allowed her to develop innovative solutions in the pharmaceutical industry.

Collaborations

Higley has collaborated with notable colleagues, including Ruth Richmond Wexler and Richard Gerald Wilde. These partnerships have contributed to her success and the advancement of her research.

Conclusion

C Anne Higley is a distinguished inventor whose work in targeted therapies for cancer and atherosclerosis showcases her commitment to improving patient outcomes. Her innovative patents and collaborations highlight her significant contributions to the pharmaceutical field.